Joel Gelfand Explained

Joel Gelfand
Education:BS, Tufts University
MD, Harvard Medical School
MSCE, University of Pennsylvania
Workplaces:Perelman School of Medicine at the University of Pennsylvania

Joel M. Gelfand is an American dermatologist and epidemiologist at the University of Pennsylvania in Philadelphia, Pennsylvania. He currently serves as the James J. Leyden Professor in Clinical Investigation, the Vice Chair of Clinical Research, the director of the Psoriasis and Phototherapy Treatment Center, and the medical director of the Clinical Studies Unit in the Department of Dermatology at the Perelman School of Medicine at the University of Pennsylvania.[1] He studies systemic comorbidities of psoriasis and much of his research has centered on the connection between cardiovascular disease and psoriasis.

Early life and education

Gelfand graduated with a bachelor's degree in biology at Tufts University, and with an MD degree from Harvard Medical School. He completed a residency in dermatology and received a Master's of Science in Clinical Epidemiology at the University of Pennsylvania. He also completed a predoctoral research fellowship in Dr. Mark Lebwohl's lab and a postdoctoral research fellowship in epidemiology at dermatologist Dr. David Margolis's lab.[2]

Career

In 2003, Gelfand joined the faculty at the Perelman School of Medicine at the University of Pennsylvania. In his early career, Gelfand published on the higher rate of cardiovascular events in patients with psoriasis in a database of United Kingdom medical records. In 2006, he published a landmark paper demonstrating that psoriasis is associated with an increased risk of myocardial infarction independent of traditional risk factors.[3] He trained cardiologist Dr. Nehal N. Mehta to study the connection between psoriasis and cardiovascular disease, and the two have collaborated extensively on subsequent research.[4]

Gelfand has published over 330 research articles with over 33,000 citations (h-index 92)[5] and is one of the most highly cited researchers in dermatology.[6] [7] His research focuses on the epidemiology of psoriasis and psoriatic arthritis, the impact of psoriasis on quality of life, and the risk of co-morbidities such as obesity,[8] diabetes,[9] hyperlipidemia, liver disease,[10] kidney disease,[11] [12] cardiovascular events,[13] and mortality[14] associated with psoriasis.[15] Notably, his research has analyzed the epidemiology of palmoplantar pustulosis and generalized pustular psoriasis in the US population,[16] the epidemiology of psoriatic arthritis in the US population,[17] and the prevalence of psoriasis in African Americans.[18] He has run numerous clinical trials, most recently including a trial on the effect of psoriasis medication apremilast on cardiovascular markers including aortic vascular inflammation using techniques pioneered with Abass Alavi,[19] a trial on patient-centered outcomes in phototherapy comparing home-based phototherapy to office-based phototherapy,[20] and a trial of a novel care coordination model to improve cardiovascular risk prevention in psoriasis patients.[4] He is funded by the NIH, PCORI, and the National Psoriasis Foundation amongst others.[21]

Gelfand has also served as part of the editorial board of the Journal of the American Academy of Dermatology, Pharmacoepidemiology and Drug Safety, and Journal of Investigative Dermatology, and as the Chief Medical Editor of Healio Psoriatic Disease.[21]

In 2021, he was named the tenured James J. Leyden Professor at the University of Pennsylvania.[22]

Honors and awards

Notes and References

  1. Web site: Joel Gelfand . Perelman School of Medicine . University of Pennsylvania.
  2. Web site: Martin . Kari . Phototherapy for Psoriasis in the Age of Biologics - Dialogues in Dermatology . AAD.
  3. Gelfand . Joel . Risk of Myocardial Infarction in Patients With Psoriasis . JAMA . 11 October 2006 . 296 . 14 . 1735–1741 . 10.1001/jama.296.14.1735 . 17032986. 631378 .
  4. Web site: Koons . Samantha . What We Are Learning About Psoriasis and Heart Disease . National Psoriasis Foundation . NPF . 31 October 2022.
  5. Web site: Joel Gelfand Scholar Profile . Google Scholar.
  6. Maymone . Mayra . Top authors in dermatology by h-index: A bibliometric analysis of 1980-2020 . Journal of the American Academy of Dermatology . July 2020 . 83 . 1 . 201–205 . 10.1016/j.jaad.2019.06.1308 . 31279031. 195819992 . free .
  7. Szeto . Mindy . Top authors in dermatology by h-index: A bibliometric analysis of 1980-2020 . Journal of the American Academy of Dermatology . December 2021 . 85 . 6 . 1573–1579 . 10.1016/j.jaad.2020.10.087 . 33217507. 227102671 . free .
  8. Love . Thorvardur . Obesity and the risk of psoriatic arthritis: a population-based study . Ann Rheum Dis . August 2012 . 71 . 8 . 1273–1277 . 10.1136/annrheumdis-2012-201299 . 22586165. 3645859 .
  9. Web site: Paddock . Catherine . Psoriasis severity may influence type 2 diabetes risk . MedicalNewsToday . 16 November 2017 . 31 October 2022.
  10. News: Rapaport . Lisa . Psoriasis tied to higher risk of serious liver disease . Reuters Health . 10 November 2017 . 31 October 2022.
  11. Web site: Jaslow . Ryan . Psoriasis may raise risk for diseases of heart, lungs, kidneys . CBS News . 7 August 2013 . CBS . 31 October 2022.
  12. Wan . Joy . Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study . BMJ . October 15, 2013 . 347 . f5961 . 10.1136/bmj.f5961 . 24129480. 3805477 .
  13. Ogdie . Alexis . Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study . Ann Rheum Dis . February 2015 . 74 . 2 . 326–332 . 10.1136/annrheumdis-2014-205675 . 25351522. 4341911 .
  14. Abuabara . K . Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. . British Journal of Dermatology. 19 August 2010 . 163 . 3 . 586–592 . 10.1111/j.1365-2133.2010.09941.x . 20633008. 2966545 .
  15. Takeshita . Junko . Psoriasis and comorbid diseases: Epidemiology . Journal of the American Academy of Dermatology . March 2017 . 76 . 3 . 377–390 . 10.1016/j.jaad.2016.07.064 . free . 28212759 . 5731650 .
  16. Noe . Megan . Evaluation of a Case Series of Patients With Palmoplantar Pustulosis in the United States . JAMA Dermatol . January 2022 . 158 . 1 . 68–72 . 10.1001/jamadermatol.2021.4635 . 34878495. 8655660 .
  17. Gelfand . Joel . Epidemiology of psoriatic arthritis in the population of the United States . Journal of the American Academy of Dermatology . October 2005 . 53 . 4 . 573 . 10.1016/j.jaad.2005.03.046 . 16198775.
  18. Gelfand . Joel . The prevalence of psoriasis in African Americans: results from a population-based study . Journal of the American Academy of Dermatology . Jan 2005 . 52 . 1 . 23–26 . 10.1016/j.jaad.2004.07.045 . 15627076.
  19. Web site: Frellick . Marcia . Apremilast May Have Some Cardiometabolic Benefits in Patients With Psoriasis . Medscape . 31 October 2022.
  20. Web site: Comparing Home- Versus Clinic-Based Phototherapy for the Treatment of Psoriasis -- The LITE Study . PCORI . 26 September 2017 .
  21. Web site: About . Gelfand Clinical Research Lab . University of Pennsylvania . 31 October 2022.
  22. Web site: Salvaryn . Georgia . Penn Medicine awards Joel M. Gelfand, MD, MSCE, the James J. Leyden Endowed Professorship . Healio . 31 October 2022.
  23. Web site: Profile . American Society for Clinical Investigation . 31 October 2022.
  24. Web site: Infanti . John . National Psoriasis Foundation honors two Penn dermatologists . EurekAlert . AAAS.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Joel Gelfand".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.